title: Phenotypic and functional characteristics of tumor-associated lymphocytes in patients with malignant ascites receiving intraperitoneal infusions of recombinant interleukin-2 (rIL-2).
abstract: In the course of a phase I trial, in which recombinant IL-2 (rIL-2) was infused intraperitoneally (i.p.) in patients with peritoneal carcinomatosis, we evaluated the effect on "tumor-associated lymphocytes" (TAL) isolated from the ascitic fluid. No major changes in the percentages of cells expressing the CD3, CD4, CD8, Leu-7, OKM1 and WT-31 antigens were detected either in TAL or in peripheral blood lymphocytes (PBL) after 7 days of rIL-2 infusion. In contrast the percentages of TAL (but not PBL) expressing surface IL-2 receptor (Tac), or LAK-1 antigen were sharply increased. Analysis of cytolytic functions showed a potentiation of the lytic activity against natural-killer (NK) sensitive K562 target cells and the de novo appearance of lytic activity against fresh melanoma cells. In one patient IFN-gamma was detected in the ascitic fluid following rIL-2 infusion. T-cell clones derived from the patient were analyzed for the IFN-gamma production. While only approximately 40% of PB-derived control clones produced medium to low amounts of IFN-gamma, all of the TAL-derived clones produced medium to high amounts of the lymphokine.
authors.affiliation: Laboratorio di Immunopatologia, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Melioli
authors.forename: E
authors.initials: E
authors.lastname: Baldini
authors.forename: M C
authors.initials: MC
authors.lastname: Mingari
authors.forename: A
authors.initials: A
authors.lastname: De Maria
authors.forename: M R
authors.initials: MR
authors.lastname: Sertoli
authors.forename: F
authors.initials: F
authors.lastname: Badellino
authors.forename: P L
authors.initials: PL
authors.lastname: Percivale
authors.forename: A
authors.initials: A
authors.lastname: Catturich
authors.forename: S
authors.initials: S
authors.lastname: Bertoglio
authors.forename: D
authors.initials: D
authors.lastname: Civălleri
mesh_terms: D001201:Ascites / Q000378:metabolism / Q000473:pathology*; D002986:Clinical Trials as Topic; D006801:Humans; D007263:Infusions, Parenteral; D007371:Interferon-gamma / Q000096:biosynthesis*; D007376:Interleukin-2 / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology*; D007694:Killer Cells, Natural / Q000187:drug effects; D008214:Lymphocytes / Q000145:classification / Q000187:drug effects* / Q000378:metabolism; D010641:Phenotype; D015375:Receptors, Interleukin-2 / Q000378:metabolism
chemical_list: D007376:Interleukin-2; D015375:Receptors, Interleukin-2; D007371:Interferon-gamma